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ABSTRACT
Cluster analysis at Postnatal Day 8–20 of putative androgen-
regulated genes in mice with Sertoli cell-selective knockout of
the androgen receptor (SCARKO) has pinpointed three genes
(Spinlw1, Gpd1, Drd4) with an expression pattern strongly
resembling that of Rhox5, the definitive Sertoli cell (SC)
androgen-regulated gene. We used organotypic testis cultures
from Day 8 mice to study control of these genes by
(anti)androgens and follicle-stimulating hormone (FSH). Testis
morphology and androgen induction of the studied genes were
preserved for 48 h. Preincubation with ketoconazole for 24 h to
block endogenous androgen production, followed by 24-h
incubation with the synthetic androgen R1881, resulted in 45-,
5-, 19-, and 6-fold induction of mRNA levels of Rhox5, Spinlw1,
Gpd1, and Drd4, respectively. However, noticeable differences
in control of the studied genes were observed. Rhox5 and
Spinlw1 were fully induced by R1881 in the continuous (48 h)
presence of ketoconazole, whereas only marginal effects were
observed on expression of Gpd1 and Drd4. Similarly, FSH only
marginally affected expression of Rhox5 and Spinlw1, whereas it
markedly increased Gpd1 and Drd4 expression. Explant cultures
of SCARKO testes confirmed the differential effects of FSH on
the studied genes and, for Gpd1, showed that the effect did not
depend on a functional androgen receptor in SC, whereas this
was essential for the effects of FSH on Drd4. In conclusion,
organotypic cultures represent the first in vitro approach to
preserving androgen responsiveness of putative SC-expressed
genes. This approach facilitates detailed analysis of their
regulation in ways not possible in vivo.
androgen receptor, bicalutamide, cell-selective knockout, follicle-
stimulating hormone, ketoconazole
INTRODUCTION
There is an overwhelming amount of evidence indicating
that optimal spermatogenesis requires both androgens and
follicle-stimulating hormone (FSH) [1–3]. Under a number of
conditions, however, androgens are able to support complete
germ cell development in the virtual absence of FSH. In mice
that are hypogonadal due to a major deletion in the Gnrh1 gene
(hpg mice), for instance, androgen administration restores
qualitatively normal spermatogenesis and even fertility [4].
Similarly, androgens maintain fertility in mice with a knockout
of the Fshb gene and in men and mice with inactivating
mutations of the FSH receptor gene (Fshr) [5–8].
The mechanisms by which androgens affect spermatogen-
esis remain incompletely understood, but the generation of
mice with a cell-selective knockout of the androgen receptor
(AR) either in germ cells [9], in peritubular myoid cells [10], or
in Sertoli cells [11–13] indicates that Sertoli cells are the major
targets of androgen action in the control of germ cell
development. Animals with a complete and selective knockout
of the AR in Sertoli cells (SCARKO), such as the SCARKO
mice, develop a spermatogenic block in meiosis [12, 13].
In rats and mice, Sertoli cells acquire androgen responsive-
ness during the first week of postnatal life [14], and AR
expression becomes detectable by immunohistochemical
techniques between Days 3 and 5 postpartum [15, 16]. In
contrast, peritubular cells stain positive for the AR already
from Day 15 postcoı¨tum onwards [17]. Expression of mRNA
encoded by Rhox5, a gene known to be selectively expressed in
Sertoli cells under the control of specific androgen response
elements located in its promoter region, was barely detectable
on Day 7 but dramatically upregulated from Day 9 postpartum
onwards [18]. Notably, microarray analysis reveals that, on
Postnatal Day 10, as many as 692 genes are differentially
expressed in SCARKO and control testes, suggesting that a
relatively large number of genes are affected by ablation of the
AR in Sertoli cells [19]. However, for only 40 of these genes is
the difference in expression level larger than 2-fold. Twenty
eight of the latter are downregulated in SCARKOs (suggesting
direct or indirect stimulation via the AR in Sertoli cells), and 12
of them are upregulated (suggesting inhibition via the AR in
Sertoli cells). Rhox5 displays the largest difference in
expression level (18-fold higher in control as compared to
SCARKO testis). Interestingly, cluster analysis of the expres-
sion profiles of the differentially expressed genes between
Days 8 and 20 revealed 14 different clusters, but 43% of the
genes with a more than 2-fold lower expression in SCARKOs
are found in one cluster (cluster 4) that also includes the Rhox5
gene [19]. Since Rhox5 is known to be directly regulated by
androgens in Sertoli cells and is also the only gene that has
been identified in all transcriptional profiling studies searching
for androgen-regulated genes in Sertoli cells [19–22], we used
hierarchical clustering of the genes in cluster 4 to identify
additional genes that might be regulated by androgens in
Sertoli cells [19]. The three genes for which the expression
pattern most strongly resembled that of Rhox5 were those
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encoding serine protease inhibitor-like protein with Kunitz and
WAP domains 1 (Spinlw1, previously known as Eppin), with
well-described effects on fertility in monkeys [23]; glycerol-3-
phosphate dehydrogenase 1 (Gpd1), an enzyme involved in
glycerol and lipid metabolism [24]; and dopamine receptor 4
(Drd4), a G-protein-coupled receptor that might modulate
responsiveness to hormones using cAMP as second messenger
[25]. Enzymatic separation of the testis into interstitial and
tubular tissue confirmed that, at least on Day 10, all of these
genes are mainly expressed in the tubular compartment [19].
Since Sertoli cells rapidly lose the expression of androgen
target genes such as Rhox5 and lose androgen responsiveness
after their isolation and culture [26, 27], we explored whether
organotypic cultures can be used to circumvent these problems.
Organotypic cultures of fetal, neonatal, and adult testis tissue
derived from rodent, monkey, and man were developed more
than 40 yr ago [28] and have been used to study testicular
development, spermatogonial proliferation and differentiation,
Sertoli cell proliferation, and germ cell progression [29–34]. To
the best of our knowledge, however, this is the first attempt to
use this experimental paradigm to study androgen-dependent
gene regulation in Sertoli cells. Here we used organotypic
cultures to study and compare the regulation of Rhox5,
Spinlw1, Gpd1, and Drd4 in the prepubertal testis in more
detail. Our data confirm androgen regulation of all studied
genes but also show that, despite a very similar behavior in
cluster analysis, each of these genes displays its own specific
pattern of regulation.
MATERIALS AND METHODS
Organotypic Cultures of Prepubertal Mouse Testes
Testes and epididymides were removed ‘‘en bloc’’ from 8-day-old
C57BL6/J@Rj mice or from 8-day-old SCARKO and control (wild type,
AMHCreþ/, or ARfl/Y) mice [12]. The tissue clumps were disinfected for 10 sec
in 50% (v/v) tincture of iodine (1%) in PBS (Invitrogen, Carlsbad, CA) and
subsequently washed twice in PBS. The testes were separated from the
epididymides in PBS, carefully decapsulated with fine forceps and scissors,
and divided into four equal parts using needle tips. The tissue pieces derived from
one testis were placed at the medium/air interface in a 15-mm Netwell insert with
a 74-lm mesh (Corning, Amsterdam, The Netherlands). Each well contained 800
ll Dulbecco modified Eagle medium/F12 medium (Invitrogen) supplemented
with vehicle, R1881 (NEN, now Perkin Elmer, Waltham, MA), hCG (Sigma, St.
Louis, MO), ovine FSH (oFSH; NIDDK-oFSH-20; obtained from Dr. Parlow
through the NIDDK program), recombinant human FSH (rhFSH; Puregon,
Organon, Oss, The Netherlands), bicalutamide (kindly provided by AstraZeneca,
Ukkel, Belgium), ketoconazole (MP Biomedicals, Solon, OH), or combinations
of these agents as indicated. Tissue cultures were maintained in 12-well plates in a
sealed incubator at 378C. The latter incubation temperature was selected because
between Days 8 and 10, in vivo testes are still located intra-abdominally and as
such are kept at body temperature. Since initial experiments revealed necrosis in
the center of the tissue clumps when the incubator was gassed with air, a 95% O
2
/
5% CO
2
mixture was used in all subsequent experiments. Tissues were cultured
for 48 h, and media and gas were changed after 24 h. Conditioned media collected
after 24 and 48 h were stored at208C for subsequent analysis of testosterone
production, as described below. Fresh decapsulated testis tissue from 8- and 10-
day-old mice was used as a reference. All animal experiments were approved by
the Ethical Committee of the Katholieke Universiteit Leuven and conducted in
accordance with the National Institutes of Health (NIH) Guide for the Care and
Use of Laboratory Animals.
At the end of the culture period, the tissue clumps were removed from the
culture mesh and snap-frozen in liquid nitrogen for RNA extraction. Tissues
destined for immunohistochemical analysis were fixed by replacing the
medium with Bouin fluid for 6 h at room temperature. Thereafter, the testis
fragments were carefully removed from the mesh, dehydrated, and further
processed into paraffin blocks using standard procedures.
Detection and Quantification of Apoptotic Cells
Apoptotic cells were identified based on DNA fragmentation detected by in
situ TUNEL as described in detail previously [35]. Briefly, DNA 30-end labeling
was carried out on tissue sections using terminal transferase and digoxygenin-11-
dUTP (both from Roche Diagnostics GmbH, Mannheim, Germany). Digox-
ygenin labeling was detected immunohistochemically (see below). Sections from
three explant samples were analyzed using a Zeiss AxioImager microscope (Carl
Zeiss Ltd., Welwyn Garden City, U.K.) fitted with a Hitachi HV-C20 camera
(Hitachi Denshi Europe, Leeds, U.K.) and a Prior automatic stage (Prior
Scientific Instruments Ltd., Cambridge, U.K.). Image-Pro 6.2 software with
Stereologer plug-in (MagWorldwide, Wokingham, U.K.) was used to select 70
random fields per sample for counting of all apoptotic cells within each field.
Immunohistochemical Staining
Specific proteins were detected by immunohistochemistry using standard
methods described in detail previously [36, 37]. Briefly, detection of AR only
required prior antigen retrieval in 0.01 M citrate buffer (pH 6.0). Endogenous
peroxidase activity was blocked by incubation of slides in 3% (vol/vol) H
2
O
2
in
methanol. Slides were incubated overnight at 48C with primary antibodies as
follows: anti-digoxygenin (Roche Diagnostics) used at a dilution of 1:100; anti-
HSD3B (Santa Cruz Biotechnology, Santa Cruz, CA) used at a dilution of
1:800; anti-CYP11A1 (Chemicon, Chandlers Ford, U.K.) used at a dilution of
1:300; and anti-AR (SC816; Santa Cruz) used at a dilution of 1:400. Slides
were then incubated with appropriate biotinylated secondary antibody,
followed by incubation with streptavidin-conjugated horseradish peroxidase
(Dako, Ely, U.K.) and visualization of immunostaining using diaminobenzidine
(Liquid DABþ; Dako). To ensure reproducibility of results and accurate
comparison of immunostaining between treatment groups, sections from all
groups were run in parallel on at least two occasions. Representative sections
were photographed using a Provis AX70 microscope (Olympus Optical,
London, U.K.) fitted with a Canon DS6031 camera (Canon Europe,
Amsterdam, The Netherlands). Images were compiled using Photoshop CS2
(Adobe Systems Inc., Mountain View, CA).
Testosterone Measurements in Conditioned Media
Conditioned medium (500 ll/testis culture) was extracted with four
volumes of cyclohexane/ethylacetate (1:1, v/v). Extraction efficiency as
measured by addition of tritiated testosterone averaged 85% 6 2% (mean 6
SEM, n¼ 25) and did not differ depending on treatment conditions. A 0.25-ml
aliquot of the extract was evaporated in a vacuum-evaporator, the residue
resuspended in charcoal-stripped human serum, and the concentration of
testosterone determined using the Testo-RIA-CT kit (Biosource International,
Camarillo, CA) according to the instructions of the manufacturer.
Quantitative PCR Analysis
RNA was extracted with the RNeasy mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions, including an on-column DNaseI-
treatment (Qiagen). Total RNA (1 lg) was reverse transcribed with the
Superscript II RNase H reverse transcription kit (Invitrogen) including
RNaseOUT (Invitrogen), according to the manufacturer’s instructions, using
150 ng random primers (Invitrogen) per reaction.
The 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City,
CA) was used for sample cDNA quantification. Spinlw1, Gpd1, and Drd4 were
assayed using SybrGreen as a fluorescent dye. The relevant primers were
described previously [19]. The quantitative PCR (qPCR) two-step protocol was
2 min at 508C followed by 2 min at 958C. Subsequently, 40 cycles of 3 sec at
958C and 30 sec at 608C were performed. Each 10-ll real-time PCR reaction
contained 13 Platinum SybrGreen qPCR Supermix-UDG (Invitrogen), 13
ROX dye (Invitrogen), 150 nM of each primer, and 2 ll of a 1/10 dilution of
the cDNA reaction. Dissociation curves confirmed uniqueness of each
amplicon. For the Rhox5 gene, a labeled probe was used as described
previously [12]. In this case, the PCR protocol was 2 min at 958C followed by
40 cycles of 3 sec at 958C and 30 sec at 608C. The reaction mixture contained
13 Taqman Fast Universal Master Mix (Applied Biosystems), 1 lM of each
primer, 400 nM probe, and 2 ll of a 1/10 dilution of the cDNA reaction.
To create standards for the quantitative PCR, gene-specific cDNAs were
generated by RT-PCR. The fragments were then cloned into pGEM-T Easy
(Promega, Madison, WI), sequenced to confirm their identity, and quantified by
spectrophotometry. All samples and standard curves were run in triplicate. Data
were analyzed with the 7500 Fast System SDS Software, version 1.4 (Applied
Biosystems). 18S rRNA was used as an internal control, and expression levels
were calculated as copy number per 108 copies 18S rRNA.
Statistical Analysis
Gene expression levels in cultured explants and testosterone levels in
conditioned media were compared by ANOVA followed by Fisher LSD test
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using NCSS 2000 software (NCSS, Statistical Analysis and Data Analysis
Software, Keysville, UT).
RESULTS
Tissue Preservation, Leydig Cell Function, and Androgen
Receptor Expression in Organotypic Cultures
Routinely, testes derived from 8-day-old mice (;4 mg/
testis) were divided into four equal parts and were maintained
in culture for 48 h as described in the Materials and Methods
section. Examination of the explants by hematoxylin and eosin
staining (data not shown) and by immunostaining for 3b-
hydroxysteroid dehydrogenase (HSD3B) at the end of the 48-h
culture period and comparison with testis tissue freshly derived
from 10-day-old mice revealed that general testis architecture
was well preserved and that culturing did not affect the number
or size of HSD3B immunopositive (Leydig) cells per cross
section (Fig. 1). Comparable results were obtained after
immunostaining for CYP11A1 (data not shown). Staining for
apoptotic cells revealed that 48 h of culture in control medium
(vehicle) resulted in a limited (approximately two-fold)
increase in the number of apoptotic cells in the interstitial
and tubular compartments as compared to freshly removed
testes of 10-day-old controls (Table 1).
Testosterone levels in media derived from vehicle-treated
cultures after the first 24 h of incubation reached a mean value
of 4.33 ng/ml, apparently reflecting active androgen secretion
(see further). These levels dropped to 1.01 ng/ml in media
collected during the second half of the 48-h culture period
(Table 2).
As illustrated in Figure 2, AR immunoexpression in vehicle-
treated cultures was comparable to that observed in freshly
derived testis tissue from 10-day-old control mice, with distinct
staining in nuclei from interstitial cells, peritubular myoid cells,
and Sertoli cells.
Organotypic Cultures Confirm Androgen Regulation
of Rhox5, Spinlw1, Gpd1, and Drd4
In a first series of experiments, we compared the effects of
the synthetic androgen R1881, the antiandrogen bicalutamide,
oFSH, and rhFSH in the organotypic cultures. None of these
treatments had noticeable effects on general testis architecture
or Leydig cell number/size per explant cross section (Fig. 1).
Ovine FSH slightly increased the number of apoptotic cells in
FIG. 1. Immunohistochemical staining for
HSD3B in testicular explants treated for 48
h with vehicle, R1881 (108 M), oFSH (20
ng/ml), bicalutamide (Bic; 105 M), or
ketoconazole (Keto; 2.105 M). Testicular
tissue derived from 10-day-old mice (Day
10) was included as a reference. Original
magnification 3200.
TABLE 1. Number of apoptotic cells in control testes and in testicular
explants.*
Experimental condition
Interstitial
compartment
Tubular
compartment
Control (Day 10) 0.02 6 0.03a 0.54 6 0.29a
Explant þ vehicle 0.06 6 0.03a 1.13 6 0.36a,c
Explant þ R1881 (108 M) 0.07 6 0.05a 1.79 6 0.49c,d
Explant þ oFSH (20 ng/ml) 0.07 6 0.04a 2.18 6 0.14d
Explant þ hCG (10 ng/ml) 0.05 6 0.05a 1.10 6 0.30a,b
Explant þ bicalutamide (105 M) 0.10 6 0.10a 1.31 6 0.23b,c
Explant þ ketoconazole (2.105 M) 0.41 6 0.15b 4.75 6 0.64e
* Apoptotic cells were counted in three explant samples (70 fields per
sample); data represent counts per field (mean 6 SD, n¼ 3).
a–e Data that differ significantly (P , 0.05) are indicated by different
superscript letters.
TABLE 2. Testosterone levels (ng/ml) in culture media after 24 or 48 h of
incubation.*
Treatment 24 h (n) 48 h (n)
Control (vehicle) 4.33 6 0.43c (6) 1.01 6 0.24b,c (5)
Bicalutamide (105 M) 2.01 6 0.36b (4) 0.43 6 0.11b,c (4)
Ketoconazole (2.105 M) 0.37 6 0.10a (5) 0.03 6 0.01a (3)
oFSH (20 ng/ml) 14.84 6 2.68d (3) 11.95 6 2.51d (3)
rhFSH (20 ng/ml) 4.29 6 0.09c (3) 1.60 6 0.74c (3)
* Values are the mean 6 SEM of the number of independent experiments
indicated between brackets. In each experiment, media from 5 organo-
typic cultures treated as indicated were assayed.
a–d Values that differ significantly (P , 0.05) are indicated by different
superscript letters.
ANDROGEN ACTION IN ORGANOTYPIC TESTIS CULTURES 1085
D
ow
nloaded from
 w
w
w
.biolreprod.org. 
the tubular compartment (Table 1). Bicalutamide reduced
testosterone levels in explant-conditioned media by approxi-
mately 50%, whereas oFSH had the opposite effect, causing a
3-fold increase (Table 2). The latter effect was not observed
with rhFSH, suggesting contamination of the oFSH preparation
with luteinizing hormone. AR immunoexpression was not
affected by R1881 or oFSH. Bicalutamide caused a marked
reduction of AR immunostaining in nuclei of interstitial cells
and Sertoli cells, whereas immunostaining in peritubular myoid
cells was not visibly affected (Fig. 2).
Transcript levels of Rhox5, Spinlw1, Gpd1, and Drd4 were
studied by quantitative PCR. To allow comparison of
expression levels observed in culture with those observed
during prepubertal development in vivo, samples derived from
organotypic cultures were processed in parallel with testis
samples freshly derived from 8- and 10-day-old mice. In the in
vivo situation, the transcript levels of Rhox5, Spinlw1, Gpd1,
and Drd4 displayed a 17.0 6 3.5, 2.8 6 0.3, 3.1 6 0.3, and
2.8 6 0.5-fold increase between Days 8 and 10 (mean 6 SEM
of seven independent experiments), confirming the observa-
tions in control animals reported previously [19]. In testis
explants cultured in control medium for 48 h (vehicle), the
expression levels were generally higher than those observed on
Day 8 in vivo, but lower than those found in vivo on Day 10
(Fig. 3).
Treatment of the organotypic cultures with the synthetic
androgen R1881 did not significantly affect the expression of
the studied genes. Bicalutamide [38], however, markedly
reduced the expression of all the studied transcripts, suggesting
that the maintenance and/or increase in the level of gene
expression observed during the 48-h culture period depends on
endogenous androgens. Neither oFSH nor rhFSH significantly
affected the transcript levels of Rhox5 or Spinlw1. Recombi-
nant human FSH significantly stimulated the transcript levels
of Gpd1 and Drd4. For oFSH the effect was significant for
Gpd1 only. Transcript levels in the presence of FSH (ovine or
recombinant human) and bicalutamide were comparable to
those observed in the presence of bicalutamide only. The
combination of FSH and R1881 tended to be more effective
than FSH only, but the effect was variable and often not
significant.
In a second series of experiments, the antiandrogen
bicalutamide was replaced by ketoconazole, an inhibitor of
steroidogenesis [39]. As expected, ketoconazole markedly
reduced the levels of testosterone in the culture media (Table
2). This drop in testosterone was accompanied by a marked
reduction in AR immunostaining in interstitial, peritubular, and
Sertoli cells (Fig. 2). Although ketoconazole did not affect the
tissue architecture of the cultured explants, a 4.2-fold increase
in apoptotic activity was noted in the tubular compartment, and
a 6.8-fold increase in the interstitium (Table 1).
In confirmation with the above-described experiments,
treatment with R1881 did not increase the transcript levels of
Rhox5, Spinlw1, Gpd1, and Drd4 above those observed in the
vehicle-treated control (Fig. 4). Treatment with ketoconazole
for 48 h markedly reduced the expression levels of all the
studied genes. Interestingly, for Rhox5 and Spinlw1, the effect
of ketoconazole could be neutralized completely by simulta-
neous treatment with exogenous androgens (R1881), whereas
this was obviously not the case for Gpd1 and Drd4. Both oFSH
and rhFSH stimulated the expression of Gpd1 and Drd4 above
that observed in the vehicle-treated control. For Rhox5 and
Spinlw1, the effects of FSH were limited and generally not
significant. For all four genes, the transcript levels in the
combined presence of FSH and ketoconazole did not differ
significantly from those observed in the presence of ketoco-
nazole only. Also, in the presence of FSH, R1881 restored the
expression levels of Rhox5 and Spinlw1 to those observed in
vehicle-treated controls. A similar restoration was not seen for
Gpd1 and Drd4.
Improved Responses to Androgens by Avoiding Prolonged
Exposure to Ketoconazole
Since androgens were apparently unable to restore Gpd1
and Drd4 expression in the continuous presence of ketocona-
zole, we explored whether transient exposure to ketoconazole
FIG. 2. Immunohistochemical staining for
the AR in testicular explants treated for 48 h
with vehicle, R1881 (108 M), oFSH (20 ng/
ml), bicalutamide (Bic; 105M), or ketoco-
nazole (Keto; 2.105 M). Testicular tissue
derived from 10-day-old mice (Day 10) was
included as a reference. Original magnifi-
cation 3400.
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FIG. 3. Hormonal control of Rhox5,
Spinlw1, Gpd1, and Drd4 in organotypic
cultures. Testicular explants from 8-day-old
mice were cultured for 48 h in control
medium (Vehicle) or in medium supple-
mented with R1881 (108 M), bicalutamide
(Bic; 105 M), oFSH (20 ng/ml), rhFSH (20
ng/ml), or combinations of these agents as
indicated. Expression levels of Rhox5,
Spinlw1, Gpd1, and Drd4 were measured
by qPCR (gray bars). As a control, expres-
sion levels were also measured in testis
samples derived from 8-day-old (Day 8) and
10-day-old (Day 10) mice processed in
parallel (open bars). All measurements were
normalized for the level of 18S rRNA and
were expressed as a percentage of the
values measured in testes from 10-day-old
mice, arbitrarily set at 100. Values indicated
are the mean 6 SEM of five independent
samples. ANOVA followed by Fisher LSD
test was used to compare expression levels
in cultured explants. Values derived from
freshly prepared Day 8 and Day 10 testes
were not included in the statistical analysis.
Values that differ significantly (P, 0.05) are
indicated by different lowercase letters (a–f).
For comparison, the value of the vehicle-
treated control is indicated as a dashed line
throughout the graph.
FIG. 4. Effects of ketoconazole, an inhib-
itor of steroidogenesis, on the ability of
androgens to stimulate the expression of
Rhox5, Spinlw1, Gpd1, and Drd4 in the
presence or absence of FSH. Testicular
explants from 8-day-old mice were cultured
for 48 h in control medium (Vehicle) or in
medium supplemented with R1881 (108
M), ketoconazole (Keto; 2.105 M), oFSH
(20 ng/ml), rhFSH (20 ng/ml), or combina-
tions of these agents as indicated. Expres-
sion levels of Rhox5, Spinlw1, Gpd1, and
Drd4 were measured by qPCR (gray bars).
As a control, expression levels were also
measured in testis samples derived from 8-
day-old (Day 8) and 10-day-old (Day 10)
mice processed in parallel (open bars).
Transcript levels were normalized, ex-
pressed, and analyzed as explained in
Figure 3. Values indicated are the mean 6
SEM of five independent samples. Values
that differ significantly (P , 0.05) are
indicated by different lowercase letters (a–
e). For comparison, the value of the vehicle-
treated control is indicated as a dashed line
throughout the graph.
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might be a better experimental approach to study the effects of
androgens in organotypic cultures. As illustrated in Figure 5, a
24-h treatment of cultures with ketoconazole was sufficient to
cause a drastic reduction in the expression of Rhox5, Spinlw1,
Gpd1, and Drd4. Removal of ketoconazole from the cultures
after 24 h and subsequent incubation for another 24 h with
control medium resulted in a significant increase in transcript
levels, demonstrating the reversibility of the effects of
ketoconazole (Fig. 5). Addition of R1881 to cultures
previously exposed for 24 h to ketoconazole restored the
expression levels of all four transcripts essentially to those
observed in cultures maintained for the entire 48 h period in
control medium. Except for Rhox5, oFSH also restored gene
expression to levels that were not significantly different from
those observed in cultures maintained for 48 h in control
medium, but the stimulation tended to be less pronounced than
that observed with R1881. Combined exposure to oFSH and
R1881 had no greater effect than R1881 alone (except for
Rhox5 where, for unexplained reasons, the combined effect
was lower; Fig. 5). In comparison to the starting conditions
(i.e., after 24 h of ketoconazole treatment), addition of R1881
caused a 45-fold induction of Rhox5 expression and a 5-fold,
19-fold, and 6-fold induction of expression for Spinlw1, Gpd1,
and Drd4, respectively. A time study at 6, 12, and 24 h under
the same conditions revealed that significant effects of
androgens could already be observed after 12 h of androgen
treatment for each of the four genes studied (data not shown).
Effects of oFSH and rhFSH on the Expression Levels
of Rhox5, Spinlw1, Gpd1, and Drd4
Dose-response curves were performed to explore the effects
of FSH on Rhox5, Spinlw1, Gpd1, and Drd4 expression in
more detail. In accordance with the data summarized in Table
2, oFSH (5–50 ng/ml) caused a dose-dependent increase in
testosterone production, whereas such an increase was not
observed for rhFSH (Supplemental Fig. S1; all Supplemental
Figures are available online at www.biolreprod.org). As shown
in Figure 6, oFSH tended to increase Rhox5 and Spinlw1
expression. In line with the observations summarized in
Figures 3 and 4, however, the effects were limited and not
always statistically significant. Moreover, no obvious dose-
response relationship could be observed. In contrast, a
significant and dose-dependent stimulatory effect of oFSH
was noted on the transcript levels of Gpd1 and Drd4. Gpd1 was
stimulated up to 4.4-fold and Drd4 up to 3.0 fold. The effects
of oFSH were strongly reduced by bicalutamide and com-
pletely blocked by ketoconazole (Fig. 6). A similar dose-
response study for rhFSH revealed similar (limited and
variable) results on Rhox5 and Spinlw1 but a dose-dependent
(up to 2.8-fold) stimulation for Gpd1 and (up to 2.4-fold)
stimulation for Drd4 (Supplemental Fig. S2).
To explore whether oFSH has effects on the expression of
Rhox5, Spinlw1, Gpd1, and Drd4 that are not dependent on the
Sertoli cell AR, testes derived from SCARKO animals and
control testes were treated for 48 h with control medium,
R1881, oFSH, or ketoconazole. As illustrated in Figure 7, the
organotypic cultures confirmed the differential expression of
all four genes in SCARKO and control testes observed also in
vivo [19]. R1881 did not affect gene expression levels either in
control testes or in SCARKO testes. In control testes, oFSH
caused a 2.1-fold and 2.7-fold increase in the expression of
Gpd1 and Drd4, respectively. In SCARKO testes a similar
increase was observed for Gpd1 (2.7-fold) but not for Drd4
(which even showed a 1.6-fold decrease). Ketoconazole
FIG. 5. Hormonal control of Rhox5,
Spinlw1, Gpd1, and Drd4 in organotypic
cultures pretreated for 24 h with ketocona-
zole. Cultures were pretreated for 24 h with
control medium (Veh) or with ketoconazole
(Keto; 2.105 M) as indicated. Thereafter
incubations were either stopped (STOP) or
continued after replacement of the medium
by control medium or by medium supple-
mented with ketoconazole (2.105 M),
R1881 (108 M), oFSH (20 ng/ml), or the
combination of R1881 and oFSH and
incubation was continued for another 24 h.
Expression levels were expressed relative to
108 copies of 18S rRNA as an internal
control, and statistical analysis was per-
formed as explained in Figure 3. Values
indicated are the mean 6 SEM of four or
five independent samples. Values that differ
significantly (P , 0.05) are indicated by
different lowercase letters (a–d).
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FIG. 7. Effect of vehicle, R1881, oFSH and
ketoconazole on gene expression in orga-
notypic cultures of SCARKO and control
testes. Testicular explants from 8-day-old
SCARKO and control mice (Ctrl) were
cultured for 48 h in control medium
(Vehicle) or in medium supplemented with
R1881 (108 M), oFSH (50 ng/ml), or
ketoconazole (Keto; 2.105 M). Expression
levels of Rhox5, Spinlw1, Gpd1, and Drd4
were measured by qPCR (control: white
bars; SCARKO: gray bars). All measure-
ments were normalized for the level of 18S
rRNA and were expressed as a percentage
of the values measured in control vehicle-
treated testes, arbitrarily set at 100. Values
indicated are the mean 6 SEM of three
independent samples. Statistical analysis
was performed as described in Figure 3.
Values that differ significantly (P, 0.05) are
indicated by different lowercase letters (a–
c).
FIG. 6. Effect of increasing doses of oFSH
on the expression of Rhox5, Spinlw1, Gpd1,
and Drd4. Testicular explants from 8-day-
old mice were treated with control medium
(Vehicle), bicalutamide (Bic; 105 M),
ketoconazole (Keto; 2.105 M), oFSH (5–50
ng/ml), or with the indicated combinations
of these agents for 48 h. Expression levels of
Rhox5, Spinlw1, Gpd1, and Drd4 were
measured by qPCR (gray bars). As a control,
expression levels were also measured in
testis samples derived from 8-day-old (Day
8) and 10-day-old (Day 10) mice processed
in parallel (open bars). Transcript levels
were normalized, expressed, and analyzed
as explained in Figure 3. Values indicated
are the mean 6 SEM of five independent
samples. Values that differ significantly (P ,
0.05) are indicated by different lowercase
letters (a–f).
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decreased the expression levels of all four genes in both control
and SCARKO testes (Fig. 7).
DISCUSSION
Recent microarray studies searching for differentially
expressed genes in testes of hypogonadal [20] or prepubertal
[21] mice treated or not treated with androgens, and in testes of
mice with ubiquitous [40] or Sertoli cell-selective [19, 22]
knockouts of the AR and controls, have disclosed a whole
series of putative androgen-regulated genes. The limited degree
of concurrence between the identified genes, however, points
to the need to investigate the role of androgens in the control of
these genes in more detail. Studies on isolated Sertoli cells
have proven of limited use for this purpose because such cells
apparently lose the expression of typical androgen-regulated
genes such as Rhox5 and also display a marked decrease in
androgen responsiveness [26, 27]. In the present series of
experiments we demonstrated that organotypic cultures of
testes derived from prepubertal mice present an excellent
alternative.
The data summarized above indicate that under the
described culture conditions, and even in the absence of
exogenously added hormones and growth factors, the mor-
phology of testis tissue derived from 8-day-old mice is well
preserved for at least 48 h. No obvious changes were noted in
the number or size of interstitial cells showing positive
immunostaining for HSD3B or in the intensity of nuclear AR
immunoexpression in interstitial cells, peritubular cells, and
Sertoli cells at the end of the 48-h culture period when
compared to testis tissue freshly derived from 10-day-old mice.
Moreover, although after the neonatal surge of androgens the
prepubertal testis is considered to enter a relatively quiescent
period [41], androgen production in the organotypic cultures—
as reflected by testosterone levels in the conditioned media—
remained high even in the absence of added gonadotropins
(approximately 4 ng/ml after the first 24 h of culture and 1 ng/
ml after the subsequent 24 h). These levels are apparently
sufficient to maintain the expression of the studied androgen-
regulated genes (Rhox5, Spinlw1, Gpd1, and Drd4). In fact,
addition of the synthetic androgen R1881 (108 M) did not
result in significant further stimulation of expression of these
genes. A similar absence of effect was observed when R1881
was replaced by testosterone (108 M) or by hCG (1–50 ng/ml;
data not shown). A disadvantage of organotypic culture
systems is that, due to the use of tissue fragments derived
from different animals, experimental variation—particularly
when comparing experiments performed on different days—
tends to be larger than in experiments using cultures of freshly
isolated cells or cell lines (Supplemental Fig. S3). With the
high number of repeats used in most experiments, however, the
observed treatment effects proved very consistent.
The dependence of the expression of Rhox5, Spinlw1, Gpd1,
and Drd4 on endogenous androgen production and action in
vehicle-treated organotypic cultures was convincingly demon-
strated by the fact that transcript levels were undetectable
(Rhox5) or markedly decreased (Spinlw1, Gpd1, Drd4) in
cultured SCARKO testes and by the observation that both the
AR antagonist bicalutamide and the inhibitor of androgen
synthesis ketoconazole markedly decreased transcript levels
after 48 h of incubation. These effects are consistent with
earlier observations [19] and with the fact that cis-acting
sequences able to act as androgen response elements have been
described at least for Rhox5 [42], Spinlw1 [43], and Gpd1 [44].
As expected, ketoconazole caused a pronounced drop in
testosterone levels in the conditioned media. Surprisingly, a
less dramatic decrease in testosterone secretion (down to
approximately 40% of the control levels) was also observed
with bicalutamide. The mechanism of the latter effect is
unclear. Androgens are known to affect adult Leydig cell
differentiation and function both directly (via the Leydig cell
AR) and indirectly (via their actions on Sertoli cells) [45, 46],
but their effects on early prepubertal Leydig cells remain to be
studied in more detail. As expected, the decrease in
testosterone levels observed after 48 h of treatment with
ketoconazole was accompanied by a marked decrease in
nuclear AR immunostaining. Bicalutamide also reduced
nuclear AR immunostaining, presumably reflecting both its
effects on androgen production and its ability to prevent stable
receptor DNA binding [47].
Cotreatment during 48 h with R1881 completely overcame
the reduction in Rhox5 and Spinlw1 expression caused by
ketoconazole but caused only a limited increase in the
transcript levels of Gpd1 and Drd4, a difference that is
puzzling and unexplained. Exposure of the organotypic
cultures to ketoconazole for 48 h increased cell apoptosis,
but this was a small effect, and if general Sertoli cell toxicity/
loss had occurred, comparable effects on the inducibility of all
four genes would have been expected, rather than just for Gpd1
and Drd4. Therefore, at the present time, the most likely
explanation for the differential effects of ketoconazole on the
inducibility of Rhox5 and Spinlw1 gene expression, on the one
hand, and on Gpd1 and Drd4 gene expression on the other
hand, is that prolonged treatment with ketoconazole (48 h)
affects the expression of the latter genes by a mechanism that is
not related to its well-known effects on androgen production,
but that could be related to its wider inhibition of P450
enzymes [48]. Such a mechanism might involve inhibition of
the production of stimulatory factors required for Gpd1 and
Drd4 expression or stimulation of inhibitory factors involved in
the control of the same genes. The nature of these
ketoconazole-affected factors warrants further investigation.
Candidates might include androgen metabolites including
estrogens (produced via the cytochrome P450-containing
enzyme CYP19A1 [aromatase]) but also unrelated steroid
derivatives and nonsteroidal molecules, such as vitamin A and
its derivatives. In the context of the use of organotypic cultures
to study androgen regulation of transcript levels, it is important
to note that these confounding effects of ketoconazole can
largely be avoided by limiting ketoconazole exposure to the
first 24 h of culture and subsequent treatment for another 24 h
with R1881 (Fig. 5).
Rhox5 and Spinlw1 also differed from Gpd1 and Drd4 with
respect to their response to FSH, which tended to increase the
expression of Rhox5 and Spinlw1 in several independent
experiments, but these effects were limited and variable. For
oFSH (20 ng/ml), mean stimulation for Rhox5 and Spinlw1, as
compared to vehicle-treated controls, averaged 1.8 6 0.3-fold
and 1.3 6 0.1-fold, respectively (mean 6 SEM; n ¼ 8).
Comparable values for rhFSH were 1.2 6 0.5-fold and 1.0 6
0.2-fold (mean 6 SEM; n ¼ 3). Moreover, no obvious dose-
response relationship could be documented. The nature of these
variable effects could not be defined further. Some contribution
of FSH-induced effects on endogenous androgen production
cannot be excluded, since the effects were more pronounced
with oFSH than with rhFSH. The possibility may also be
considered, however, that the observed effects are indirect and
that, for instance, in the absence of any exogenously added
growth factors, FSH may stimulate the production of
endogenously produced growth factors, such as IGF or
transferrin, that improve the viability and functionality of the
cultured explants [49–51].
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In contrast, Gpd1 and Drd4 displayed consistent and dose-
dependent increases in transcript levels in the presence of FSH.
This increase was observed in the presence of oFSH (which
increases endogenous testosterone production, Supplemental
Fig. S1) as well as rhFSH (which did not affect testosterone
production), supporting the contention that it is a genuine FSH
effect. Mean stimulation for Gpd1 and Drd4 with oFSH (20 ng/
ml) was 2.9 6 0.3-fold and 2.7 6 0.2-fold, respectively (n ¼
8). Corresponding values with rhFSH were 2.3 6 0.8-fold and
2.7 6 0.7-fold, respectively (n ¼ 3). In line with the above-
discussed effects of ketoconazole on the expression of these
genes, the effects of FSH were completely blocked in the
presence of ketoconazole. Surprisingly, however, bicalutamide
also interfered with the effects of FSH on Gpd1 and Drd4
expression, suggesting that androgens may play a permissive
role in the observed FSH effects. To explain the apparent
paradox that increased endogenous androgen production does
not seem to play a role in the effects of FSH on Gpd1 and Drd4
expression, but that interference with androgen action largely
or completely blocks these effects, the role of the Sertoli cell
AR in the effects of FSH on Gpd1 and Drd4 responses was
investigated by comparing the effects of FSH in organotypic
cultures derived from wild-type and SCARKO mice. The data
summarized in Figure 7 clearly show that an active AR in
Sertoli cells is required for oFSH-dependent stimulation of
Drd4 but not for Gpd1. We can only speculate on the
mechanism by which bicalutamide also reduces the effect of
FSH on Gpd1. This effect might be due in part to the
bicalutamide-induced reduction in androgen production and/or
to the inhibition by bicalutamide of androgen-controlled factors
permissive for FSH-induced Gpd1 expression produced by
non-Sertoli cells (such as peritubular myoid cells). An
alternative explanation for the above-mentioned paradox might
be that FSH increases the maximally achievable response to
androgens in Sertoli cells (e.g., by increasing AR levels), as
previously described in Sertoli cell-enriched cultures [52]. At
present we can only state that the immunohistochemical results
summarized in Figure 2 do not show a noticeable increase in
Sertoli cell AR concentration in FSH-treated explants. It is
obvious, however, that more research will be needed to clarify
the molecular mechanisms responsible for the observed FSH
effects.
In conclusion, organotypic culture systems such as the one
described here represent an excellent tool to study the control
of putative androgen-regulated genes in more detail. By
preserving normal testis architecture and thus allowing normal
cell-cell interactions, the organotypic testis cultures increase
the chance of detecting physiologically relevant effects and cell
interactive effects. In this way, the system overcomes many of
the limitations (loss of gene expression, loss of androgen
responsiveness) observed with Sertoli cell-enriched cultures.
Preincubation for 24 h with ketoconazole to block endogenous
androgen production, followed by a period of treatment with
exogenous androgens, may be an optimal setup to study the
androgen responsiveness of putative target genes. The system
can also successfully be used to study the interaction of
androgens with other hormones (FSH) or factors controlling
the expression of the relevant genes. The present data clearly
confirm that Rhox5, Spinlw1, Gpd1, and Drd4 are targets for
androgen action, and they also stress that the regulation of
Rhox5 and Spinlw1 differs considerably from that of Gpd1 and
Drd4, despite a very closely related behavior in cluster
analysis. FSH has only limited effects on the expression of
Rhox5 and Spinlw1 but markedly increases the transcript levels
of Gpd1 and Spinlw1. For Gpd1 the latter effect does not
depend on the simultaneous activation of the Sertoli cell AR,
whereas for Drd4, oFSH is inactive in the absence of a
functional AR in Sertoli cells.
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